| Jun 18, 2026 | finder.startupnationcentral.org | RedHill Biopharma Announces Up To $19.4 Million Private Placement |
| Jun 18, 2026 | www.prnewswire.com | RedHill Biopharma Announces Up To $19.4 Million Private Placement |
| Jun 9, 2026 | finance.yahoo.com | RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation |
| Jun 9, 2026 | www.prnewswire.com | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer... |
| Jun 8, 2026 | finance.yahoo.com | RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo |
| Jun 8, 2026 | www.prnewswire.com | /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has... |
| Jun 2, 2026 | finance.yahoo.com | RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms |
| Jun 2, 2026 | www.prnewswire.com | Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or... |
| Apr 30, 2026 | finance.yahoo.com | RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease |
| Apr 30, 2026 | www.prnewswire.com | RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-1042, designed for enhanced tolerability, safety profile and patient adherence, that... |
| Apr 27, 2026 | finance.yahoo.com | RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights |
| Apr 27, 2026 | www.prnewswire.com | 2025 was a year of tenacity, strategic transactions and building traction for RedHill Talicia® business transformed: Formation of Talicia Holdings Inc. (THI)... |
| Apr 22, 2026 | www.prnewswire.com | RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 |
| Apr 22, 2026 | www.prnewswire.com | New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects... |
| Feb 25, 2026 | finance.yahoo.com | Joint U.S. Commercialization of RedHill's Talicia® Commences |
| Feb 25, 2026 | finance.yahoo.com | CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA® |
| Feb 25, 2026 | www.prnewswire.com | The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity... |
| Jan 5, 2026 | finance.yahoo.com | RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects |
| Dec 15, 2025 | finance.yahoo.com | RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells |
| Dec 1, 2025 | finance.yahoo.com | RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement |
| Dec 1, 2025 | www.prnewswire.com | /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on November 26,... |
| Nov 4, 2025 | finance.yahoo.com | RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement |
| Nov 4, 2025 | www.prnewswire.com | /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York... |
| Oct 22, 2025 | finance.yahoo.com | RedHill Biopharma Receives Nasdaq Staff Determination Notification |
| Oct 22, 2025 | www.prnewswire.com | On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the... |
| Oct 20, 2025 | finance.yahoo.com | RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal |
| Oct 20, 2025 | www.prnewswire.com | Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business U.S.... |
| Oct 20, 2025 | finance.yahoo.com | CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO |
| Oct 6, 2025 | finance.yahoo.com | RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia® |
| Oct 6, 2025 | www.prnewswire.com | The deal aims to accelerate Talicia's entry into new Middle East markets Under the terms of the agreement RedHill will receive $500,000 in guaranteed payments,... |
| Sep 29, 2025 | www.prnewswire.com | The New York Supreme Court has, on appeal, upheld its original summary judgment ruling in favor of RedHill The New York Supreme Court unequivocally dismissed... |
| Sep 29, 2025 | finance.yahoo.com | RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo |
| Sep 5, 2025 | finance.yahoo.com | RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights |
| Aug 20, 2025 | finance.yahoo.com | RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win |
| Aug 20, 2025 | www.prnewswire.com | /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York... |
| Aug 18, 2025 | finance.yahoo.com | RedHill Received Talicia® Licensing Payments Totaling $1.1 Million |
| Aug 18, 2025 | www.prnewswire.com | RedHill has received its first Talicia sales milestone payment as well as royalties and other payments, totaling $1.1 million, following the first ex-U.S.... |
| Jul 21, 2025 | www.prnewswire.com | The positive FDA feedback allows for: A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium... |
| Jul 21, 2025 | finance.yahoo.com | RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease |
| Jul 1, 2025 | finance.yahoo.com | Sector Update: Health Care Stocks Rise in Late Afternoon Trading |
| Jul 1, 2025 | finance.yahoo.com | RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer |
| Jul 1, 2025 | www.prnewswire.com | Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer... |
| May 13, 2025 | finance.yahoo.com | RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win |
| May 2, 2025 | finance.yahoo.com | RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress |
| Apr 28, 2025 | finance.yahoo.com | RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107 |
| Apr 28, 2025 | www.prnewswire.com | Strong Use of Composition-of-Matter Coverage: Patent protects the molecular structure of RHB-107, providing market exclusivity beyond method-of-use claims... |
| Apr 17, 2025 | finance.yahoo.com | RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency |
| Apr 16, 2025 | finance.yahoo.com | RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption |
| Apr 10, 2025 | finance.yahoo.com | RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights |
| Mar 31, 2025 | uk.finance.yahoo.com | Surrey loses rush-hour taxis to thousands of school runs |
| Mar 18, 2025 | finance.yahoo.com | RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation |
| Mar 18, 2025 | www.prnewswire.com | RedHill plans to submit UK MAA1 for Talicia for H. pylori infection, using MHRA's2 new fast-track approval process, referencing FDA approval, with potential UK... |
| Mar 12, 2025 | www.prnewswire.com | The planned innovative Phase 2 study of RHB-2041 will be the first ever clinical study in Crohn's Disease (CD) patients who are all MAP-positive, and will... |
| Mar 12, 2025 | finance.yahoo.com | RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results |
| Feb 27, 2025 | www.prnewswire.com | Guy Goldberg, RedHill's Chief Business Officer, presents today a business update at the European Life Sciences CEO Forum The update covers: The recent... |
| Feb 27, 2025 | finance.yahoo.com | RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum |
| Feb 26, 2025 | www.pharmaceutical-technology.com | RedHill and Hyloris sign agreement for Bekinda’s development |
| Feb 25, 2025 | www.prnewswire.com | - Hyloris will pay RedHill an upfront payment and up to $60 million in potential milestone payments, plus up to mid-20s percent royalties on revenues, in... |
| Feb 25, 2025 | finance.yahoo.com | RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties |
| Feb 5, 2025 | www.clinicaltrialsarena.com | RedHill Biopharma launches trial of combination therapy for prostate cancer |
| Feb 4, 2025 | finance.yahoo.com | RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer |
| Feb 4, 2025 | www.prnewswire.com | The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with... |
| Feb 4, 2025 | www.prnewswire.com | The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with... |
| Jan 21, 2025 | finance.yahoo.com | RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published |
| Dec 10, 2024 | finance.yahoo.com | Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development |
| Dec 3, 2024 | finance.yahoo.com | RedHill Biopharma awarded judgement of approx $8M by NY Supreme Court |
| Dec 2, 2024 | finance.yahoo.com | RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court |
| Dec 2, 2024 | www.prnewswire.com | /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Company has... |
| Oct 28, 2024 | finance.yahoo.com | RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND |
| Oct 23, 2024 | finance.yahoo.com | RedHill Biopharma and Duke Collaborate on Opaganib Development |
| Oct 22, 2024 | www.prnewswire.com | RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury |
| Oct 14, 2024 | www.prnewswire.com | RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment |
| Oct 1, 2024 | www.prnewswire.com | RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians |
| Oct 1, 2024 | finance.yahoo.com | RedHill Biopharma Secures Opaganib COVID-19 Patent |
| Sep 30, 2024 | www.prnewswire.com | RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041 |
| Sep 9, 2024 | www.prnewswire.com | RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines |
| Sep 5, 2024 | www.prnewswire.com | /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received... |
| Sep 5, 2024 | www.prnewswire.com | RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement |
| Sep 3, 2024 | www.prnewswire.com | New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality |
| Aug 29, 2024 | www.prnewswire.com | RedHill Biopharma Announces First Half 2024 Business Highlights |
| Aug 29, 2024 | www.prnewswire.com | A transformed RedHill: Numerous potential catalysts Strengthened cash balance and control over our destiny following the Termination Agreement with Movantik... |
| Aug 26, 2024 | www.prnewswire.com | RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma |
| Aug 21, 2024 | www.prnewswire.com | Talicia® Launched in the United Arab Emirates |
| Aug 21, 2024 | finance.yahoo.com | Three Undiscovered Gems in the United States Market |
| Aug 19, 2024 | finance.yahoo.com | Upcoming Stock Splits This Week (August 19 to August 23) – Stay Invested |
| Aug 19, 2024 | www.prnewswire.com | RedHill Announces Positive Obesity and Diabetes Results with Opaganib |
| Aug 16, 2024 | www.prnewswire.com | RedHill Biopharma Announces Plan to Implement ADS Ratio Change |
| Aug 1, 2024 | www.prnewswire.com | Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease |
| Jul 22, 2024 | www.prnewswire.com | RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien |
| Jul 9, 2024 | www.prnewswire.com | RedHill Biopharma Terminates License Agreement for Aemcolo® |
| Jun 3, 2024 | www.prnewswire.com | RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040 |
| May 22, 2024 | uk.finance.yahoo.com | Pensioners win £9,000 back in 16-year council tax battle |
| May 6, 2024 | www.prnewswire.com | RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 |
| Apr 24, 2024 | www.prnewswire.com | RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study |
| Apr 10, 2024 | finance.yahoo.com | RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022) |
| Apr 8, 2024 | www.prnewswire.com | RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights |
| Apr 2, 2024 | www.prnewswire.com | RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price |
| Mar 11, 2024 | www.prnewswire.com | RedHill Announces New USPTO Patent Covering Talicia® Through 2034 |
| Mar 5, 2024 | www.prnewswire.com | RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs |
| Feb 20, 2024 | www.prnewswire.com | RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication |